Topical ketoconazole: a systematic review of current dermatological applications and future developments

References

• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10:1–10.
   PubMed Web of Science ®Google Scholar
• Faergemann J, Borgers M, Degreef H. A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism. Expert Opin Pharmacother. 2007;8:1365–1371.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm362415.htm [Accessed 2018 April 20].
   Google Scholar
• Gupta AK, Lyons DCA. The rise and fall of oral ketoconazole. J Cutan Med Surg. 2015;19:352–357.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc. Nizoral Shampoo Label. 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021738lbl.pdf [Accessed 2018 April 21].
   Google Scholar
• Center for Drug Development and Research. Nizoral AD pharmacology review. 1997. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20310_NIZORALA-D 1%25_pharmr.pdf [Accessed 2018 April 21].
   Google Scholar
• TEVA Pharmaceuticals. Ketoconazole cream label. 2000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/75-581_Ketoconazole_prntlbl.pdf [Accessed 2018 April 21].
   Google Scholar
• Stiefel Laboratories Inc. Extina label. 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021738lbl.pdf [Accessed 2018 April 21].
   Google Scholar
• Aqua Pharmaceuticals. Xolegel label. 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021946s005lbl.pdf [Accessed 2018 April 21].
   Google Scholar
• US Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2018. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm [Accessed 2018 April 21].
   Google Scholar
• US Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. 2018. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021946&Appl_type=N [Accessed 2018 April 21].
   Google Scholar
• Grover C, Bansal S, Nanda S, et al. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br J Dermatol. 2007;157:364–368.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. J Fungi (Basel). 2015;1:13–29.
   PubMedGoogle Scholar
• Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182:127–141.
   PubMed Web of Science ®Google Scholar
• Karray M, MKinney WP. Tinea, versicolor. Petersburg (FL): StatPearls Publishing; 2018.
   Google Scholar
• Hafeez F, Hui X, Chiang A, et al. Transungual delivery of ketoconazole using novel lacquer formulation. Int J Pharm. 2013;456:357–361.
   PubMed Web of Science ®Google Scholar
• Mahtab A, Anwar M, Mallick N, et al. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech. 2016;17:1477–1490.
   PubMed Web of Science ®Google Scholar
• Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7:77–86.
   PubMedGoogle Scholar
• Shrestha S, Jha AK, Pathak DT, et al. Ketoconazole or clotrimazole solution wash as a prophylaxis in management and prevention of fungal infection: a comparative study. Nepal Med Coll J. 2013;15:31–33.
   PubMedGoogle Scholar
• Bseiso E, Nasr M, Abd El Gawad N, et al. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol. 2015;81:457.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul. 2005;22:501–510.
   PubMed Web of Science ®Google Scholar
• Patel MR, Patel RB, Parikh JR, et al. Investigating effect of microemulsion components: in vitro permeation of ketoconazole. Pharm Dev Technol. 2011;16:250–258.
   PubMed Web of Science ®Google Scholar
• Deng P, Teng F, Zhou F. Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. Mater Sci Eng C. 2017;78:296–304.
   PubMed Web of Science ®Google Scholar
• Patel RP, Patel H. Baria AH. Formulation and evaluation of liposomes of ketoconazole. Int J Drug Deliv Technol. 2009;1:16–23.
   Google Scholar
• Shirsand S, Kanani K, Keerthy D, et al. Formulation and evaluation of ketoconazole niosomal gel drug delivery system. Int J Pharm Investig. 2012;2:201.
   PubMedGoogle Scholar
• Guo F, Wang J, Ma M, et al. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med. 2015;26:1–13.
   Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Katsambas A, Antoniou C, Frangouli E, et al. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream . Br J Dermatol. 1989;121:353–357.
   PubMed Web of Science ®Google Scholar
• Skinner RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol. 1985;12:852–856.
   PubMed Web of Science ®Google Scholar
• Stratigos JD, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-blind comparative study. J Am Acad Dermatol. 1988;19:850–853.
   PubMed Web of Science ®Google Scholar
• Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venerol. 2007;21:345–350.
   PubMed Web of Science ®Google Scholar
• Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116:217–221.
   PubMed Web of Science ®Google Scholar
• Pari T, Pullmood S, Jacob M, et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venerol. 1998;10:89–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9552768 [Accessed 2018 May 4].
   PubMed Web of Science ®Google Scholar
• Wannanukul S, Chiabunkana J. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis. J Med Assoc Thail. 2004;87(2):S68–S71.
   PubMedGoogle Scholar
• Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006;5:646–650.
   PubMedGoogle Scholar
• Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001–1008.
   PubMedGoogle Scholar
• Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132:441–445.
   PubMed Web of Science ®Google Scholar
• Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm Venereol. 1990;70:171–172.
   PubMed Web of Science ®Google Scholar
• Go IH, Wientjens DP, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses. 2009;35:103–105.
   Google Scholar
• Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol. 1987;116:213–216.
   PubMed Web of Science ®Google Scholar
• Arrese JE, Piérard-Franchimont C, De Doncker P, et al. Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutis. 1996;58:235–237.
   PubMed Web of Science ®Google Scholar
• Piérard-Franchimont C, Piérard GE, Arrese JE, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202:171–176.
   PubMed Web of Science ®Google Scholar
• Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat. 2007;18:88–96.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Kenneally DC, Hodges LT, et al. A comparison of hair quality and cosmetic acceptance following the use of two anti-dandruff shampoos. J Investig Dermatol Symp Proc. 2005;10:201–204.
   PubMedGoogle Scholar
• Piérard-Franchimont C, Goffin V, Decroix J, et al. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Physiol. 2002;15:434–441.
   Web of Science ®Google Scholar
• Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008–1012.
   PubMed Web of Science ®Google Scholar
• Cauwenbergh G, De Doncker P, Schrooten P, et al. Treatment of dandruff with a 2% ketoconazole scalp gel. A double-blind placebo-controlled study. Int J Dermatol. 1986;25:541.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Lacour JP, Vitetta A, et al. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184:275–280.
   PubMed Web of Science ®Google Scholar
• Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol. 1986;15:500–503.
   PubMed Web of Science ®Google Scholar
• Balwada R, Jain V, Dayal S. A double-blind comparison of 2% ketokonazole and 1% clotrimazole in the treatment of pityriasis versicolor. Indian J Dermatol Venereol Leprol. 1996;62:298–300.
   PubMedGoogle Scholar
• Nagpal VB, Jain VK, Aggarwal K. Comparative study of oral and topical ketoconazole therapy in pityriasis versicolor. Indian J Dermatol Venereol Leprol. 2003;69:287–288.
   PubMedGoogle Scholar
• Chopra V, Jain V. Comparative study of topical terbinafine and topical ketokonazole in pityriasis versicolor. Indian J Dermatol Venereol Leprol. 2000;15:500–503.
   Google Scholar
• Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 1998;39:944–950.
   PubMed Web of Science ®Google Scholar
• Di Fonzo EM, Martini P, Mazzatenta C, et al. Comparative efficacy and tolerability of Ketomousse? (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: results of a prospective, multicentre, randomised study. Mycoses. 2008;51:532–535.
   PubMed Web of Science ®Google Scholar
• Shi TW, Zhang JA, Tang YB, et al. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J Dermatolog Treat. 2015;26:143–146.
   PubMed Web of Science ®Google Scholar
• Greer D, Jolly HW. Comparative trial of a two-dosage schedule of ketoconazole 2% cream for the treatment of tinea pedis. J Am Acad Dermatol. 1987;17:53–56.
   PubMed Web of Science ®Google Scholar
• Greer DL. Topical treatment for moccasin-type tinea pedis. J Am Acad Dermatol. 1987;16:554–558.
   PubMed Web of Science ®Google Scholar
• Suschka S, Fladung B, Merk HF. Clinical comparison of the efficacy and tolerability of once 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. Mycoses. 2002;45:91–96.
   PubMed Web of Science ®Google Scholar
• Khozeimeh F, Shahtalebi MA, Noori M, et al. Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of candida-infected denture stomatitis. J Contemp Dent Pract. 2010;11:17–24.
   Google Scholar
• Török I, Stehlich G. Double-blind comparative examination of ketoconazole 1% cream and clotrimazole 2% ointment in superficial dermatomycosis. Ther Hung. 1993;41:60–63.
   PubMedGoogle Scholar
• Piérard-Franchimont C, De Doncker P, Cauwenbergh G, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196:474–477.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29:489–498.
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Aminjavaheri M, Omidghaemi MR. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat. 2003;14:26–29.
   PubMedGoogle Scholar
• Nelson ME, Midgley G, Blatchford NR. Ketoconazole in the treatment of blepharitis. Eye. 1990;4:151–159.
   PubMed Web of Science ®Google Scholar
• Okokon E, Verbeek J, Ruotsalainen J, et al. Topical antifungals for seborrhoeic dermatitis (review) summary of findings for the main comparison. Cochrane Database Syst Rev. 2015;5:CD008138.
   Google Scholar
• Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91:185–190.
   Web of Science ®Google Scholar
• Danby FW. Oral ketoconazole in dermatology: where are we now? Medscape infectious diseases. 2013. Available from: https://www.medscape.com/viewarticle/809906 [Accessed 2018 June 21].
   Google Scholar
• Beetens JR, Loots W, Somers Y, et al. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol. 1986;35:883–891.
   PubMed Web of Science ®Google Scholar
• De Pedrini P, Rapisarda R, Spanò G. The effect of ketoconazole on sebum secretion in patients suffering from acne and seborrhoea. Int J Tissue React. 1988;10:111–113.
   PubMedGoogle Scholar
• Van Cutsem J, Van Gerven F, Cauwenbergh G, et al. The antiinflammatory effects of ketoconazole: a comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea pigs. J Am Acad Dermatol. 1991;25:257–261.
   PubMed Web of Science ®Google Scholar
• Suzuki C, Hase M, Shimoyama H, et al. Treatment outcomes for Malassezia folliculitis in the dermatology department of a university hospital in Japan. Japanese J Med Mycol. 2016;57:E 63–E.66.
   Google Scholar
• Fujita W. Safety and efficacy of ketoconazole 2% foam in the treatment of pityrosporum folliculitis – full text view – clinicalTrials.gov. Bethesda (MD): National Library of Medicine; 2014. https://clinicaltrials.gov/ct2/show/NCT00824863 [Accessed 2018 June 21].
   Google Scholar
• Anane S, Chtourou O, Bodemer C, et al. Malassezia folliculitis in an infant. Med Mycol Case Rep. 2013;2:72–74.
   PubMedGoogle Scholar
• Hamaguchi T, Nagase M, Higuchi R, et al. A case of confluent and reticulated papillomatosis responsive to ketoconazole cream. Jpn J Med Mycol. 2002;43:95–98.
   Google Scholar
• Kang S, Jee M, Choi J, et al. A case of infantile acne due to Pityrosporum. Pediatr Dermatol. 2003;20:68–70.
   PubMed Web of Science ®Google Scholar
• Gaitanis G, Mayser P, Scheynius A, et al. Malassezia yeasts in seborrheic and atopic eczemas. Malassezia and the skin. Heidelberg, Berlin: Springer Berlin Heidelberg; 2010. p. 201–228.
   Google Scholar
• Darabi K, Hostetler SG, Bechtel MA, et al. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:125–136.
   PubMed Web of Science ®Google Scholar
• Harada K, Saito M, Sugita T, et al. Malassezia species and their associated skin diseases. J Dermatol. 2015;42:250–257.
   PubMed Web of Science ®Google Scholar
• Rosenberg EW, Noah PW, Skinner RB, et al. Microbial associations of 167 patients with psoriasis. Acta Derm Venereol Suppl (Stockh). 1989;146:72–74.
   PubMedGoogle Scholar
• Baroni A, Paoletti I, Ruocco E, et al. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients. J Cutan Pathol. 2004;31:35–42.
   PubMed Web of Science ®Google Scholar
• Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;3:CD001434.
   Web of Science ®Google Scholar
• Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Int J Dermatol. 1998;37:64–71.
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Saúl A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol. 2000;10:107–109.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Onumah N. Use of naftifine hydrochloride 2% cream and 39% urea cream in the treatment of tinea pedis complicated by hyperkeratosis. J Drugs Dermatol. 2014;13:162–165.
   PubMed Web of Science ®Google Scholar
• Carrillo-Muñoz AJ, Tur-Tur C, Cárdenes DC, et al. Sertaconazole nitrate shows fungicidal and fungistatic activities against trichophyton rubrum, trichophyton mentagrophytes, and epidermophyton floccosum, causative agents of tinea pedis. Antimicrob Agents Chemother. 2011;55:4420–4421.
   PubMed Web of Science ®Google Scholar
• Nigam PK, Boktor SW. Tinea, pedis. Petersburg (FL): StatPearls Publishing; 2018. http://www.ncbi.nlm.nih.gov/pubmed/29262247 [Accessed 2018 April 25].
   Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48:503–535.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Bukhalo M, Blauvelt A. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17:329–336.
   PubMed Web of Science ®Google Scholar
• Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964–973.
   PubMed Web of Science ®Google Scholar
• Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62:112–115.
   PubMed Web of Science ®Google Scholar
• Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem. 1989;33:251–255.
   PubMedGoogle Scholar
• Masubuchi Y, Akaike M, Kumai T, et al. Disturbance or relatively important actions of antihypertensives, antifungal agent and opiate antagonist to the testicular steroidogenesis in rat. J Toxicol Sci. 1992;17:41–50.
   PubMedGoogle Scholar
• Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res. 1992;24:367–370.
   PubMed Web of Science ®Google Scholar
• Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984;2:433–435.
   PubMed Web of Science ®Google Scholar
• Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol. 1996;35:770–778.
   PubMed Web of Science ®Google Scholar
• Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317:812–818.
   PubMed Web of Science ®Google Scholar
• Jiang J, Tsuboi R, Kojima Y, et al. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. J Dermatol. 2005;32:243–247.
   PubMed Web of Science ®Google Scholar
• Aldhalimi MA, Hadi NR, Ghafil FA. Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. ISRN Pharmacol. 2014;2014:1–5.
   Google Scholar
• Piérard G, Piérard-Franchimont C, Nikkels-Tassoudji N, et al. Improvement in the inflammatory aspect of androgenetic alopecia. A pilot study with an antimicrobial lotion. J Dermatolog Treat. 1996;7:153–157.
   Web of Science ®Google Scholar
• Piérard GE, Piérard-Franchimont C, Cutsem J, et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol. 1991;30:806–809.
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11:415–429.
   PubMed Web of Science ®Google Scholar
• Wali JP, Aggarwal P, Gupta U, et al. Ketoconazole in treatment of visceral leishmaniasis. Lancet. 1990;336:810–811.
   PubMed Web of Science ®Google Scholar
• Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990;89:147–155.
   PubMed Web of Science ®Google Scholar
• Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology. 1997;114:S91–S99.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res. 2006;123:345–352.
   PubMed Web of Science ®Google Scholar
• Beach DH, Goad LJ, Holz GG. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol. 1988;31:149–162.
   PubMed Web of Science ®Google Scholar
• Hart DT, Lauwers WJ, Willemsens G, et al. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol Biochem Parasitol. 1989;33:123–134.
   PubMed Web of Science ®Google Scholar
• Derbel M, Benzina Z, Ghorbel I, et al. Malassezia fungal blepharitis: a case report. J Fr Ophtalmol. 2005;28:862–865.
   PubMed Web of Science ®Google Scholar
• Heeres J, Backx LJ, Mostmans JH, et al. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem. 1979;22:1003–1005.
   PubMed Web of Science ®Google Scholar
• De Almeida HL, Dallazem RN, Dos Santos LS, et al. Bilateral tinea nigra in a temperate climate. Dermatol Online J. 2007;13:7–10.
   Google Scholar
• Burke WA. Tinea nigra: treatment with topical ketoconazole. Cutis. 1993;52:209–211.
   PubMed Web of Science ®Google Scholar
• Selvin SST, Korah SMG, Michael JS, et al. Series of five cases of Papulaspora equi keratomycosis. Cornea. 2014;33:640–643.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA adverse event reporting system public dashboard. 2018. Available from: https://fis.fda.gov/sense/app/777e9f4d-0cf8-448e-8068-f564c31baa25/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis [Accessed 2018 April 21].
   Google Scholar
• European Medicines Agency. Eudravigilance. 2018. Available from: https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages [Accessed 2018 April 21].
   Google Scholar
• Shelanski M, Phillips S, Potts C. Evaluation of cutaneous reactivity to recently marketed dermatologic products. Int J Dermatol. 1996;35:137–140.
   PubMed Web of Science ®Google Scholar
• van Ketel WG. An allergic eruption probably caused by ketaconazole. Contact Derm. 1983;9:313–335.
   PubMed Web of Science ®Google Scholar
• Liu J, Warshaw EM. Allergic contact dermatitis from ketoconazole. Cutis. 2014;94:112–113.
   PubMed Web of Science ®Google Scholar
• Dooms-Goossens A, Matura M, Drieghe J, et al. Contact allergy to imidazoles used as antimycotic agents. Contact Derm. 1995;33:3–77.
   Web of Science ®Google Scholar
• Hausen BM, Angel M. Studies on the sensitizing capacity of imidazole and triazoles. Dermatitis. 1992;3:95–101.
   Google Scholar
• Lazzarini R, Hafner MFS, Miguel BAF, et al. Allergic contact dermatitis caused by topical ketoconazole: a relevant issue? Review of ketoconazole-positive patch tests. Contact Derm. 2018;78:234–236.
   PubMed Web of Science ®Google Scholar
• Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: a review of safety profiles. J Eur Acad Dermatol Venereol. 2017;31:1440–1446.
   PubMed Web of Science ®Google Scholar
• Lind J. Limb malformations in a case of hydrops fetalis with ketoconazole use during pregnancy. Arch Gynecol. 1985;237:398.
   Google Scholar